TBPH
Theravance Biopharma Inc
17.00$
+0.0%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -7.6% | -2.8% | -2.5% | -1.6% | -0.5% | -3.0% | +24.0% | -2.5% | +16.9% | -2.7% | -0.5% | |
| – | -17.4% | -6.9% | -4.0% | -2.4% | +38.3% | -6.7% | +143.8% | -3.2% | +18.0% | -0.2% | -0.2% | |
| – | -44.8% | +36.1% | -13.9% | -49.6% | +61.7% | +192.7% | +154.9% | -38.0% | -4.0% | +71.7% | -23.7% | |
| – | -23.6% | -2.4% | -3.9% | -4.9% | -3.3% | +48.1% | +158.9% | -2.7% | -4.3% | +25.1% | -1.8% | |
| – | +2.4% | -16.1% | -2.5% | +17.8% | +306.3% | -77.6% | +42.8% | -16.7% | +423.0% | -83.7% | +30.8% | |
| – | -100.0% | – | – | – | – | – | – | – | – | – | – | |
| – | +0.9% | -1.5% | +1.1% | +1.3% | +4.8% | -0.6% | +13.3% | -9.1% | +3.3% | -3.8% | -0.9% | |
| – | -2.4% | -12.5% | +5.9% | +2.1% | +36.9% | -1.8% | +73.4% | -31.5% | +2.4% | -17.0% | -3.2% | |
| – | -59.6% | +3.6% | +3.8% | -0.5% | +155.3% | +0.9% | +0.8% | +0.2% | +0.3% | -1.8% | +0.4% | |
| – | -35.6% | +10.6% | -0.7% | -13.1% | +54.2% | +7.4% | -30.4% | +32.1% | +16.0% | -57.2% | -40.7% | |
| – | -13.5% | -3.8% | -5.5% | -4.1% | -5.4% | -5.4% | +35.5% | +3.5% | +27.5% | -2.1% | -0.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -5.6% | -2.3% | +1.0% | +0.6% | +0.5% | +0.8% | +2.1% | +2.3% | +2.2% | -3.3% | +0.8% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.